Forge Leadership

CO-FOUNDERS AND MANAGEMENT

Seth Cohen, Ph.D.
Scientific Co-Founder

David Puerta, Ph.D.
Co-Founder & Science Advisor

Zachary Zimmerman, Ph.D.
Co-Founder & Director

Andrew Tomaras, Ph.D.
Chief Science Officer & President

BOARD OF DIRECTORS

Brian Dorsey, M.S.
Partner of Magna
Sci Ventures
Mario Polywka, D.Phil.
Former COO of Evotec AG
John Schmid, MBA
Former CFO of Trius and Auspex Pharmaceuticals
Steve Worland, Ph.D.
President and CEO of eFFECTOR Therapeutics
Zachary Zimmerman, Ph.D.
Co-founder

ANTIBIOTICS ADVISORY BOARD

Michael Barbachyn, Ph.D.
Co-inventor of the antibiotics linezolid (marketed as Zyvox) and sutezolid, and former director-level contributor to antibacterial discovery at Pharmacia, Pfizer and AstraZeneca.
Seth Cohen, Ph.D.
Scientific co-founder of Forge, professor and former Chair of the Department of Chemistry and Biochemistry at the University of California, San Diego.
Karen Joy Shaw, Ph.D.
Current Chief Scientific Officer of Amplyx Pharmaceuticals and former SVP Biology at Trius Therapeutics leading the microbiology strategy for Tedizolid development; former Antibacterial Team Leader Johnson & Johnson and Schering Plough.
Lynn Silver, Ph.D.
Involved in the discovery of the first inhibitors of LpxC, and the development of the antibiotic Invanz at Merck where she held the title of senior investigator.
Peter Warn, Ph.D.
Former SVP Anti-Infective Discovery at Evotec and Chief Science Officer at Euprotec
Lloyd Payne, D.Phil.
Founding CEO of specialty anti-infectives CRO Euprotec, former Executive Vice President and Head of Anti-infectives at Evotec and current member of Novo REPAIR’s Scientific Selection Board

INVESTORS

PARTNERS

MEDIA REQUESTS:

Amy@Juniper-Point.com